IDEAYA Biosciences and Hengrui Pharma Present Positive Phase 1 Data for IDE849 (SHR-4849), a Potential First-in-Class DLL3 TOP1 ADC, in Small Cell Lung Cancer at the IASLC 2025 World Conference on Lung Cancer

About this update from Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class A

[{"type":"list","items":[{"val":[{"type":"text","content":"80.0% (8/10) ORR and 70.0% (7/10) confirmed ORR in 2L SCLC; a 73.7% (14/19) ORR and 57.9% (11/19) confirmed ORR (1 pending confirmation) were observed across all lines of SCLC at the 2.4 mg/kg expansion dose of IDE849","length":217,"tagName":"p"}]},{"val":[{"type":"text","content":"77.1% (27/35) ORR and 60.0% (21/35) confirmed ORR (4 pending confirmation) in 2L SCLC; a 73.2% (52/71) ORR and 47.9% (34/71) confirmed ORR (10 pending confirmation) were observed across all lines of SCLC at all expansion doses of IDE849","length":236,"tagName":"p"}]},{"val":[{"type":"text","content":"In patients with baseline brain metastases, a 83.3% (5/6) confirmed ORR at the 2.4 mg/kg dose was observed; across all doses ≥2.4 mg/kg (n=18), a 66.7% (12/18) confirmed ORR (1 pending confirmation) was observed","length":211,"tagName":"p"}]},{"val":[{"type":"text","content":"14.1% (10/71) of patients across all doses >2.4 mg/kg are still pending confirmation, as well as multiple patients that have had limited follow-up (e.g. one post-baseline scan) highlighting the study has not yet achieved a fully mature confirmed ORR%","length":253,"tagName":"p"}]},{"val":[{"type":"text","content":"6.7 month median progression free survival (PFS) across all lines of SCLC across all dose levels (≥2.4 mg/kg); mPFS not reached in 2L SCLC patients","length":147,"tagName":"p"}]},{"val":[{"type":"text","content":"Manageable safety profile observed across multiple expansion cohorts, including the 2.4 mg/kg, 3.0 mg/kg, and 3.5 mg/kg dose levels with a once every 3-week dosing interval","length":172,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":1236,"olType":false},{"type":"text","content":"SHANGHAI and SOUTH SAN FRANCISCO, Calif., Sept. 7, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, and Hengrui Pharma, a global pharmaceutical company focused on scientific and technological innovation, presented initial data from Hengrui's Phase 1 clinical trial of IDE849 (SHR-4849), a potential first-in-class delta-like ligand 3 (DLL3)-targeting Topoisomerase-1 (TOP1) antibody drug conjugate (ADC), in an oral presentation today at the IASLC 2025 World Conference on Lung Cancer (WCLC) in Barcelona, Spain. The presentation included data from a total of 100 patients who receive...

More updates from Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class A